Annual Report 2003 Aventis - Sanofi

Brand names appearing in italics throughout this report are trademarks of Aventis and/or its affiliates, with the exception of:
- trademarks used or that may be used under license by Aventis and / or its affiliates, such as Actonel, a trademark of the Group
Procter & Gamble Pharmaceuticals, Alvesco, a trademark of the Group ALTANA Pharma AG, Campto, a trademark of the Group
Kabushiki Kaisha Yakult Honsha, Copaxone, a trademark of the Group Teva Pharmaceutical Industries, DiaPep277, a trademark
of Peptor Ltd, Exubera, a trademark of the Group Pfizer Products Inc., Genasense, a trademark of Genta Inc. in the U.S., Tavanic,
a trademark of the Group Daiichi Pharmaceutical Co. Ltd. and Mutagrip, a trademark of Institut Pasteur.
- Claritin, a trademark of Schering Corporation
Information Regarding Forward-Looking Statements
Statements in this annual report other than historical information are forward-looking statements subject to risks and uncertainties.
The forward-looking statements in this document speak only of management’s views as at March 1, 2004. Factors that could cause
actual results to differ materially from those expressed or implied include, but are not limited to, impediments to the realization of
integration cost savings as a result of labor or political issues or the difficulties of integrating large and complex businesses while
continuing day-to-day operations, continued evolutions in the business and business environment, actions that may be taken by
competitors or by regulatory authorities, unexpected negative results from research and development of current product candidates,
the effectiveness of patent protection, the result of litigation and other risks and uncertainties that are difficult to predict. There can
be no assurance that we will achieve the results set forth above. Additional information regarding risks and uncertainties is set forth
in the current Annual Report on Form 20-F of Aventis on file with the U.S. Securities and Exchange Commission.
This report has been provided for information purposes only. Aventis prepares a legally binding annual report in the French language
known as the “Document de Référence” prior to its Annual General Meeting of Shareholders as well as an annual report in the
English language on Form 20-F pursuant to the U.S. Securities Exchange Act of 1934.
All reports can be ordered by phone: 00 800 40 53 43 40 (toll-free) or +49 6192 9 77 08 28
or by e-mail: Aventis@mt-w.de
They can also be downloaded from our Web site at www.aventis.com
Aventis, a stock corporation with a Supervisory Board and Management Board, and a share capital of e 3 064 758 522.74 – 542 064 308
RCS Strasbourg